NASDAQ:EBIO - Eleven Biotherapeutics Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00
+0.30 (1.20%)
Get New Eleven Biotherapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EBIO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EBIO

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Eleven Biotherapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for EBIO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Eleven Biotherapeutics. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/29/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/10/2018LaidlawInitiated CoverageBuy$8.00High
4/18/2018HC WainwrightSet Price TargetBuy$2.00Low
4/12/2018HC WainwrightSet Price TargetBuy$2.00Medium
3/20/2018HC WainwrightInitiated CoverageBuy$2.00High
(Data available from 6/21/2016 forward)
Eleven Biotherapeutics logo
Sesen Bio, Inc. engages in designing, engineering, and developing of targeted protein therapeutics. It offers the Vicinium and Proxinium which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.
Read More

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

15,575,300 shs

Average Volume

2,864,343 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Eleven Biotherapeutics?

The following equities research analysts have issued reports on Eleven Biotherapeutics in the last twelve months:
View the latest analyst ratings for EBIO.

What is the current price target for Eleven Biotherapeutics?

0 Wall Street analysts have set twelve-month price targets for Eleven Biotherapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Eleven Biotherapeutics in the next year.
View the latest price targets for EBIO.

What is the current consensus analyst rating for Eleven Biotherapeutics?

Eleven Biotherapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for EBIO.

What other companies compete with Eleven Biotherapeutics?

How do I contact Eleven Biotherapeutics' investor relations team?

Eleven Biotherapeutics' physical mailing address is 215 FIRST STREET SUITE 400, CAMBRIDGE MA, 02142. The biopharmaceutical company's listed phone number is (617) 444-8550 and its investor relations email address is [email protected] The official website for Eleven Biotherapeutics is www.elevenbio.com.